The Mario Lombardo award has been assigned to Dr. Raffaella Gioia, a young ophthalmologist recently specialized at the Magna Graecia University of Catanzaro. The celebration was held at the Regensight Research & Development Lab. in Reggio C ...
The first “Mario Lombardo” Research Award goes to Dr. Raffaella Gioia
We are pleased to award the "Mario Lombardo" Research Prize to Dr. Raffaella Gioia, who ha been recently specialized in Ophthalmology at the Magna Graecia University of Catanzaro. We at Regensight award the commitment of Raffaella to the study and mana ...
Mario Lombardo Research Award
Glad to promote the Mario Lombardo Research Award. The award will be assigned to a young research devoted to the research & development of new methods and techniques for the prevention, diagnosis and treatment of keratoconus. For more information ...
New scientific publication showing efficacy of theranostics for the treatment of keratoconus
A new scientific research was recently published in the prestigious Journal of Biophotonics. The study shows the pre-clinical efficacy results of the innovative theranostic-guided corneal cross-linking procedure for the treatment of keratoconus. The s ...
Regensight’s new R&D laboratory
Regensight announces that a new research & development unit has been established in the metropolitan city of Reggio calabria and that it will be active from 1 September 2022. The laboratory, strongly desired by the co-founders, was created to stren ...
Multicenter Randomized Clinical Trial RSKC001 started
We are pleased to announce the start of the multicenter randomized clinical trial aiming at assessing theranostic-guided corneal cross-linking for treatment of keratoconus. The clinical trial is conducted at three of the major Italian Universities devo ...
Theranostic-guided corneal cross-linking randomized clinical study granted by the Ministry of Health
We are pleased to communicate that the randomized clinical study RSKC001 has been granted by the Italian Ministry of Health according to new Medical Device Regulation (MDR) 2017/745.The scope of the study is to validate the theranostic-guided corneal cro ...
First installation of C4V CHROMO4VIS
Pleased to announce the installation of C4V CHROMO4VIS at the INVISTA eyeclinic in Rome (Italy).The UV-A medical device is no available to eye surgeons who want to improve their care to young patients afflicted by keratoconus with the most advanced state ...
Innovup award to Regensight
Very nice time spent in Genova among the Meet in Italy for Life Sciences 2021 finalists. Happy to be awarded by Innovup-Italian Innovation & Startup Ecosystem!
First mission: solving the lifetime societal burden of keratoconus
Regensight ha la missione di migliorare la vita ai giovani pazienti affetti da cheratocono